Zero Hedge
The FDA has warned old people to stop infusing plasma from young people in order to slow down the aging process, saying it has "no proven clinical benefit" according to Bloomberg.
In a Tuesday safety alert, the agency suggested that old people getting scammed with $8,000 per liter plasma to treat age-related issues including dementia, Parkinson's disease, Alzheimer's disease and heart disease.
"There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat or prevent these conditions, and there are risks associated with the use of any plasma product," reads a statement from FDA Commissioner Scott Gottlieb and Peter Marks, who leads the agency's biologics center.
The FDA has warned old people to stop infusing plasma from young people in order to slow down the aging process, saying it has "no proven clinical benefit" according to Bloomberg.
In a Tuesday safety alert, the agency suggested that old people getting scammed with $8,000 per liter plasma to treat age-related issues including dementia, Parkinson's disease, Alzheimer's disease and heart disease.
"There is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat or prevent these conditions, and there are risks associated with the use of any plasma product," reads a statement from FDA Commissioner Scott Gottlieb and Peter Marks, who leads the agency's biologics center.
The idea of infusing young blood to fight aging has attracted technology entrepreneurs like billionaire Peter Thiel and was lampooned in a 2017 episode of the HBO show “Silicon Valley.” Thiel’s reported interest was sparked by a company called Ambrosia, which has locations in five states across the U.S. and sells one liter of blood plasma from donors between the ages of 16 and 25 for $8,000, according to its website.Read more
Gottlieb and Marks said none of the plasma treatments has gone through the rigorous testing required by the agency. Ambrosia says “experiments in mice called parabiosis provided the inspiration to deliver treatments with young plasma.” The FDA approval typically requires human trials before companies can make a specific health claim about a product.
No comments:
Post a Comment